论文部分内容阅读
目的探讨尿激酶静脉溶栓治疗急性心肌梗死的临床疗效。方法对46例确诊为AMI且符合溶栓条件的患者进行溶栓以及规范化治疗,并进行对症处理。结果 46例患者中26例发病6h内溶栓,其中24例溶解,2例未通;26例患者发病6～24h溶栓,其中15例溶解,6例未通;再通者中1例因反复梗死并发心力衰竭而死亡,2例因室颤死亡,未溶解病例中死亡2例。结论尿激酶静脉溶栓治疗AMI安全有效、价格快捷,不良反应少,可为抢救心肌赢得时间,降低AMI患者的病死率,适宜在基层医院推广。
Objective To investigate the clinical effect of intravenous thrombolytic therapy of urokinase on acute myocardial infarction. Methods Thirty-six patients diagnosed as AMI who were eligible for thrombolytic therapy underwent thrombolysis and standardization therapy and were given symptomatic treatment. Results Twenty-six of the 46 patients developed thrombolysis within 6h, of which 24 were dissolved and 2 failed. Thirty-six of 26 patients developed thrombolysis within 6 to 24h, of which 15 were dissolved and 6 failed. One of the recanalization Repeated infarction complicated by heart failure and death, 2 patients died of ventricular fibrillation, two cases of undivided death. Conclusions Urokinase intravenous thrombolysis is safe and effective, quick in price and less in adverse reactions. It can save time for myocardial rescue and reduce mortality in patients with AMI. It is suitable for promotion in primary hospitals.